Organized around four case studies, the discussion will focus on current clinical evidence for optimal selection of immunotherapy and use of combination therapy. Topics covered include monitoring for and managing irAEs, care coordination and communication with non-oncology specialists, and assessment of institution- or practice-specific gaps in IO integration. Shared decision-making, reimbursement, and survivorship will also be discussed.
This activity is supported by an educational grant from Bristol-Myers Squibb Company.
This activity is a part of the IC-ONC collaborative.